After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field…

As the UK extracts itself from the European Union, key figures from the country's life sciences sector are split on the implications of Brexit for…

Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of…

Eisai has a history of more than 40 years in Indonesia. In fact, the country was one of the first places for the Group to expand into outside of…

As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared…

Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is…